Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017

  • ID: 4330521
  • Report
  • Region: Global
  • 77 Pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cempra Inc
  • Eisai Co Ltd
  • RaQualia Pharma Inc
  • Wockhardt Ltd
  • Yooyoung Pharm Co Ltd
  • Yuyu Pharma Inc
  • MORE
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 5, 5 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cempra Inc
  • Eisai Co Ltd
  • RaQualia Pharma Inc
  • Wockhardt Ltd
  • Yooyoung Pharm Co Ltd
  • Yuyu Pharma Inc
  • MORE
Introduction

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development

Ahn-Gook Pharmaceutical Co Ltd

Cempra Inc

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Takeda Pharmaceutical Company Ltd

Wockhardt Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles

(lansoprazole + omeprazole) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceclazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEM-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-3710 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-17DT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilaprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IW-3718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-1366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenatoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YY-DXR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYD-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones

Featured News & Press Releases

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day

Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride

Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age

Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea

Jan 27, 2016: FDA Approves Takeda’s Dexilant SoluTab (dexlansoprazole)

Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting

Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease

Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease

Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union

Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union

Oct 15, 2013: TWi Pharmaceuticals Comments on Dexilant Ruling

Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision

Nov 17, 2011: Takeda Provides Update On DEXILANT Product Labeling

Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra Inc, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017 (Contd..1), H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017 (Contd..2), H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2017 (Contd..1), H2

List of Figures:

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ahn-Gook Pharmaceutical Co Ltd
  • Cempra Inc
  • Daewoong Pharmaceutical Co Ltd
  • Eisai Co Ltd
  • Ilyang Pharmaceutical Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Takeda Pharmaceutical Company Ltd
  • Wockhardt Ltd
  • Yooyoung Pharm Co Ltd
  • Yuyu Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll